News | May 30, 2025
Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Annual EBITDA margin expands by 170 basis points
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
The initiative was announced at World Hypertension Congress, Chennai
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Akums invested Rs. 272 crore in capital expenditure during FY25
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Subscribe To Our Newsletter & Stay Updated
